SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.


EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.


Account Information

LEAVE THIS BLANK

By selecting this, I agree to receive emails from celltelligence.com.


Already have an account? Log in here

Adaptimmune and GSK Agree to Terms for PRAME and NY-ESO Programs Transfer; Kristin Yarema to Serve as Poseida’s President for Cell Therapy; Mythili Koneru Appointed as Legend’s CMO

Here is a brief preview of this blast: On Tuesday, April 11, Adaptimmune announced (press release) the terms of the agreement with GSK for transferring back PRAME and NY-ESO programs. On the same day, Poseida and Legend reported the appointments of Kristin Yarema as Poseida’s Cell Therapy President (press release) and Mythili Koneru as Legend’s CMO (press release). Below, Celltelligence provides insights on the transition of GSK’s PRAME and NY-ESO programs back to Adaptimmune, while discussing the potential benefits of the new appointments for Poseida and Legend.

About The Author

The Celltelligence Team

|
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.